Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Clinical trial NCT02624570 · NO_LONGER_AVAILABLE

Trial details

NCT number: NCT02624570
Sponsor: Novartis Pharmaceuticals
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS

Acute Myeloid Leukemia (AML) With FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.